



HTRF KinEASE-STK S2 kit

Part # 62ST2PEB, 62ST2PEC & 62ST2PEJ

Test size: 1,000 tests (62ST2PEB), 20,000 tests (62ST2PEC), 100,000 tests (62ST2PEJ)

Revision: #05 of September 2023

Assay volume: 20 μ L

Store at: 2-8°C

This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes.

ASSAY DESCRIPTION

HTRF® KinEASE-STK S2 is a generic method for measuring Serine/Threonine kinase activities. More than 150 kinases have been tested with the KinEASE universal detection system, using 3 different substrates (visit our website at: www.revvity.com).


The HTRF® KinEASE-STK S2 assay format involves the two steps described below:

1. Enzymatic step:

During this step, the kinase will phosphorylate the substrate. The STK Substrate 2-biotin is incubated with the kinase. ATP is added to start the enzymatic reaction.


2. Detection step:

The detection reagents will catch the phosphorylated substrate. The resulting TR-FRET signal is proportional to the phosphorylation level. The STK-Antibody labeled with Eu³⁺-Cryptate and streptavidin-XL665 are mixed in a single addition with EDTA (used to stop the kinase activity).



MANUAL AT A GLANCE

ADD



READ & ANALYSE

Incubate 1 hour @ RT



MATERIALS:

| Kit components | 1,000 tests Cat # 62ST2PEB | 20,000 tests Cat # 62ST2PEC | 100,000 tests Cat # 62ST2PEJ |
|---|---------------------------------|---------------------------------|----------------------------------|
| STK Substrate 2-biotin <i>Lyophilized</i> | 1 vial of 50 µg # 61ST2BLE* | 1 vial of 500 µg # 61ST2BLC* | 3 vials of 500 µg # 61ST2BLC* |
| Streptavidin-XL665 MW: 60 KDa <i>Lyophilized</i> | 1 vial of 250 µg # 610SAXLA* | 1 vial of 3 mg # 610SAXLG* | 5 vials of 3 mg # 610SAXLG* |
| STK Antibody-Cryptate <i>Lyophilized</i> | 1 vial of 1,000 tests | 1 vial of 20,000 tests | 5 vials of 20,000 tests |
| Enzymatic buffer 5X | 1 vial of 10mL # 62EZBFDC* | 1 vial of 50mL # 62EZBFDD* | 5 vials of 50mL # 62EZBFDD* |
| Detection buffer (contains EDTA) <i>Ready to use</i> | 1 vial of 40 mL # 62SDBRDD* | 1 vial of 200 mL # 62SDBRDF* | 5 vials of 200 mL # 62SDBRDF* |

* These kit reagents are also available separately

ADDITIONAL MATERIAL - NOT PROVIDED

| | Recommended supplier* | Stock solution to prepare |
|---------------------------------|--|--------------------------------|
| HTRF 96-well low volume plate** | Revvity # 66PL96001 | |
| Kinase | Upstate - follow supplier's instructions | follow supplier's instructions |
| ATP | Sigma # A7699 | 5 mM in 50 mM Hepes buffer |

* Suppliers' names are indicative

**For HTRF microplate recommendations, please visit www.revvity.com

For reading, an HTRF®-compatible reader is needed. Make sure to use the setup for Eu³⁺ Cryptate.

For a list of HTRF®-compatible readers and setup recommendations, please visit www.revvity.com

- The enzymatic buffer must be supplemented with any components required by the kinase of interest. You will find details for all the validated enzymes in the technical notes posted on our website at: www.revvity.com.

| | Recommended supplier* | Stock solution to prepare |
|-------------------|-----------------------|-----------------------------|
| DTT | Sigma # D0632 | 100 mM in distilled water |
| CaCl ₂ | Sigma # 21115 | 1 M (ready to use) |
| MgCl ₂ | Sigma # M1028 | 1 M (ready to use) |
| AMP | Sigma # A1752 | 5 mM in distilled water |
| cGMP | Sigma # G6129 | 1 mM in distilled water |
| Lipid activator | Upstate # 20-133 | 10x solution (ready to use) |
| Calmodulin | Upstate # 14-368 | 100 µM in distilled water |

* Suppliers' names are indicative

STORAGE AND STABILITY

Store the kit at 2-8°C or below. Under appropriate storage conditions, reagents are stable until the expiry date indicated on the label.

After reconstitution, the stock solutions can be stored 1 week at +4°C or dispensed into single use aliquots and stored at -20°C. The volume of antibody aliquots should not be under 10 µL.

Enzymatic and detection buffer can be stored at 2-8°C on your premises.

REAGENT PREPARATION

BEFORE YOU BEGIN:

- It is very important to prepare the reagents in the specified buffers. The use of an incorrect diluent may affect reagent stability and assay results.
- Before use, allow all reagents to warm up at room temperature.
- Homogenize buffers with a vortex.
- It is recommended to filter buffers before use.
- Detection reagent solutions must be prepared in individual vials and can be mixed prior to dispensing.

TAKE CARE TO PREPARE STOCK AND WORKING SOLUTIONS ACCORDING TO THE DIRECTIONS FOR THE KIT SIZE YOU HAVE PURCHASED.






PREPARATION OF WORKING SOLUTIONS:

- Working solutions cannot be stored and must be used immediately, except for the STK Antibody-Cryptate which can be stored 1 week at +4°C or dispensed into single use aliquots and stored at -20°C.
- In order to avoid degradation, the enzyme working solution must be kept in an ice bath for the time of the experiment.
- The enzymatic buffer 5X does contain 0.05% BSA but is not supplemented with nonionic surfactants. The surfactant of your choice can be added in case of aggregation or sticking issue.
- DTT diluted in the enzymatic buffer is stable one day at 2-8°C.
- HTRF® detection reagent concentrations have been set for optimal assay performances. Note that any dilution or improper use of the XL665 and Cryptate-conjugates will impair the assay's quality.

| Buffer preparation | |
|--|--|
| Kinase buffer = 1X supplemented enzymatic buffer | Dilute 1 volume of enzymatic buffer 5X with 4 volumes of distilled water and complement it with all the supplements required by the kinase of interest, i.e. DTT, MgCl ₂ , CaCl ₂ , Calmodulin, etc. (for informations about validated kinases, see application notes on www.revvy.com). |
| Detection buffer | Ready to use |

| Reagent preparation | 1,000 tests | 20,000 tests | 100,000 tests |
|----------------------------------|--|---|---------------|
| STK Substrate 2-biotin | For 1,000 tests size kit 1. Reconstitute the vial of 50 µg with distilled water to obtain a 50 µM STK Substrate 2-biotin stock solution (refer to product label). 2. Dilute the 50 µM STK Substrate 2-biotin stock solution with 1X kinase buffer to prepare the working solution which has 5X the required final concentration for the enzymatic step (10 µL). E.g. For 10 nM final concentration, prepare a 50 nM working solution: dilute 1000-fold the reconstituted 50 µM STK Substrate 2-biotin stock solution | For 20,000 tests and 100,000 tests size kit 1. Reconstitute the vial of 500 µg with distilled water to obtain a 500 µM STK Substrate 2-biotin stock solution (refer to product label). 2. Dilute the 500 µM STK Substrate 2-biotin stock solution with 1X kinase buffer to prepare the working solution which has 5X the required final concentration for the enzymatic step (10 µL). E.g. For 10 nM final concentration, prepare a 50 nM working solution: dilute 10000-fold the reconstituted 50 µM STK Substrate 2-biotin stock solution | |
| Streptavidin-XL665 MW: 60 Kda | 1. Reconstitute each vial (250µg or 3 mg) with distilled water to obtain a 16.67 µM Streptavidin stock solution (refer to product label). 2. Dilute the 16.67 µM Streptavidin stock solution with detection buffer to prepare a working solution which has 4X the required final concentration for the final volume assay (20 µL). E.g. For 125 nM final concentration, prepare a 500 nM working solution: dilute 33.3-fold the reconstituted 16.67 µM Sreptavidin-XL665 stock solution. | | |
| STK Antibody-Cryptate | For 1,000 tests size kit Reconstitute the vial of 1,000 tests with 5 mL of Detection buffer to get the ready to use STK-antibody-cryptate solution. | For 20,000 tests and 100,000 tests size kit 1. Reconstitute the vial of 20,000 tests with 2 mL of distilled water to get a 50X STK-antibody-cryptate intermediate solution. 2. To obtain the final 1X STK-antibody-cryptate working solution, dilute 50-fold the STK-antibody-cryptate intermediate solution with the detection buffer. E.g. Add 98 mL of detection buffer to 2 mL of intermediate STK-antibody-cryptate intermediate solution. | |
| Compounds | Dilute compound stock solution with kinase buffer to prepare a working solution which has 2.5X the required final concentration for the enzymatic step (10 µL). | | |
| Kinase | Dilute the kinase stock solution with kinase buffer to prepare a working solution which has 5X the required final concentration for the enzymatic step (10 µL). | | |
| ATP | Dilute the ATP stock solution (5 mM) with kinase buffer to prepare a working solution which has 5X the required final concentration for the enzymatic step (10 µL). E.g. For an ATP 100 µM in the enzymatic step, prepare a 500 µM ATP working solution. | | |

ASSAY MANUAL

| | | Kinase assay | Negative |
|---|---|---|--|
| | | Enzymatic step - 10 µL | |
| 1 |  | 4 µL of compounds* 2 µL of STK Substrate 2-biotin 2 µL of kinase 2 µL of ATP** | 4 µL of compounds* 2 µL of STK Substrate 2-biotin 2 µL of kinase buffer 2 µL of ATP** |
| 2 |  | Seal the plate and incubate*** at room temperature or 37°C. | |
| | | Detection step - 10 µL | |
| 3 |  | 5 µL of Streptavidin-XL665 5 µL of STK Antibody-cryptate | |
| 4 |  | Seal the plate and incubate 1 hour at room temperature. | |
| 5 |  | Remove the plate sealer and read on an HTRF® compatible reader. | |

- * For low volume compound addition, adjust volume to 4 µL with 1x kinase buffer. Keep DMSO ≤ 2% in the enzymatic step.
- ** The kinase reaction is started by the addition of ATP (Enzymatic step) and is stopped by the addition of the detection reagents which contain EDTA (detection step). The incubation time is dependent on the activity of the kinase tested.
- *** The incubation period for the enzymatic step is optimized depending on the kinase.

DATA REDUCTION & INTERPRETATION

1. Calculate the ratio of the acceptor and donor emission signals for each individual well.

$$\text{Ratio} = \frac{\text{Signal 665 nm}}{\text{Signal 620 nm}} \times 10^4$$

2. Calculate the delta ratio of the acceptor and donor emission signals for each individual well. The Negative control plays the role of an internal assay control.

$$\text{delta Ratio} = \text{Ratio Standard or sample} - \text{Ratio Standard 0}$$

3. Calculate the % CVs. The mean and standard deviation can then be worked out from ratio replicates.

$$\text{CV (\%)} = \frac{\text{Standard deviation}}{\text{Mean Ratio}} \times 100$$

For more information about data reduction, please visit www.revvity.com

OPTIMIZATION OF A KINASE ASSAY

A typical development for an HTRF® KinEASE™-STK assay consists of the following steps:

1. Substrate selection (only possible with HTRF® KinEASE™-STK Discovery kit)
2. Enzyme titration
3. Kinetic study
4. Substrate titration
5. ATP titration
6. Biotin/streptavidin ratio optimization
7. Inhibitor IC₅₀ determination

Final concentrations of the assay components used for kinase assay optimization are:

| | | Conc. Max. | Conc. Min. |
|------------------------|---|----------------------|--------------------------|
| STK-Substrate 2-biotin | Final conc. in the enzymatic step (10 µL) | 2 µM | 0.97 nM |
| Kinase | | 10 ng/well (1 ng/µL) | 0.1 ng/well (0.01 ng/µL) |
| ATP | | 300 µM | 1.7 nM |
| Sa-XL665 | Final conc. in the final assay volume (20 µL) | 125 nM | 0.06 nM |
| STK Antibody-Cryptate | | Ready to use | Ready to use |

1. SUBSTRATE SELECTION

The HTRF® KinEASE™-STK Discovery kit which contains all 3 substrates enables the substrate selection test to be run. This step is required for a given kinase not listed in the tables of the KinEASE web product page at www.revvy.com

The kinase should be tested with each substrate following the assay manual described above. We recommend testing the kinase at the concentration of 10 ng/well* (20 µL final volume) with STK substrate1, 2 or 3-biotin (1 µM)*, and a saturating concentration of ATP (100 µM)*. Allow the enzymatic reaction to run for 30 min at RT. Add the detection reagents. The biotin/ streptavidin molar ratio must be 8/1 (i.e. 62.5 nM Sa-XL665**).

The enzymatic activity observed with one of the 3 peptides indicates the optimal substrate to use.

* Final concentrations in the enzymatic step (10 µL).

** Final assay concentration (20 µL).

2. ENZYME TITRATION

This step enables the optimal enzyme concentration (for which the signal reaches 80% of the maximum) to be determined.

A compromise may be found between a high assay signal and the enzyme consumption.

For this step, a fixed concentration of the STK Substrate 2-biotin (1 µM) and ATP (100 µM) should be tested with the following enzyme concentrations: 10; 2; 1; 0.1 ng/well. Allow the enzymatic reaction to run for 30 mn. The biotin/streptavidin ratio of 8/1 must be used (i.e. 62.5 nM Sa-XL665).

3. KINETIC STUDY

Enzyme kinetic depends on the kinase and substrate concentrations.

A time course study is performed using a constant concentration of kinase (determined in the previous experiment), ATP (100 µM) and substrate (1 µM). The reaction is stopped at different end points by the addition of the detection reagents (1, 2, 5, 10, 15, 30, 60 min).

The biotin /streptavidin ratio must remain constant and equal to 8/1 (i.e. 62.5 nM Sa-XL665).

The signal is then plotted versus the different end points. Determine the linear part of the time course (correlation coefficient R² > 0.99) and from this section, the optimal incubation time to use for the next experiments.

4. SUBSTRATE TITRATION

This step enables the determination of substrate Km (app). Use the optimal enzyme concentration and a saturating ATP concentration (100 µM). We recommend testing different STK substrate-biotin concentrations ranging from 2 µM to 0.97 nM (two-fold serial dilutions). The kinase reaction is stopped at the previously determined optimal incubation period. During the detection step, it will be necessary to adjust the concentration of the SA-XL665 for each STK substrate-biotin concentration, in order to keep the biotin/streptavidin ratio constant at 8/1 as described in the following table. Furthermore, since the background may rise with increasing XL665 concentrations, it is necessary to run a negative control (no enzyme) for each Sa-XL665 concentration.

| STK Substrate-biotin | | Sa-XL665 |
|---|---------------------------|---------------------------|
| Final conc. in the enzymatic step (10 µL) | Final assay conc. (20 µL) | Final assay conc. (20 µL) |
| 2 µM | 1 µM | 0.125 µM |
| 1 µM | 0.5 µM | 62.50 nM |
| 0.5 µM | 0.25 µM | 31.25 nM |
| 0.25 µM | 0.125 µM | 15.61 nM |
| 0.125 µM | 62.50 nM | 7.81 nM |
| 62.50 nM | 31.25 nM | 3.90 nM |
| 31.25 nM | 15.61 nM | 1.95 nM |
| 15.61 nM | 7.81 nM | 0.97 nM |
| 7.81 nM | 3.90 nM | 0.48 nM |
| 3.90 nM | 1.95 nM | 0.24 nM |
| 1.95 nM | 0.97 nM | 0.12 nM |
| 0.97 nM | 0.485 nM | 0.06 nM |

The plot of the specific signal (ratio sample (with enzyme) – ratio negative) versus the substrate concentrations is then fitted to Michaelis-Menten or Lineweaver-Burke equations to calculate the substrate Km (app).

5. ATP TITRATION

This step enables the determination of ATP Km (app). Use the optimal enzyme concentration and a saturating STK-Substrate 2-biotin concentration (1 µM). We recommend testing ATP concentrations ranging from 300 µM to 1.7 nM (three-fold serial dilutions). The kinase reaction is stopped at the optimal incubation period by adding the detection reagents. During the detection step, the biotin/streptavidin ratio must be fixed at 8/1 (62.5 nM SA-XL665). As in the previous step, the Km (app) value must be determined from this experiment using either a Michaelis-Menten or a Lineweaver-Burke plot.


6. BIOTIN/STREPTAVIDIN RATIO OPTIMIZATION

The optimization of the biotin/streptavidin ratio is an important step which may lead to a substantial increase in signal. Streptavidin-XL665 solutions are prepared in order to cover 2/1, 4/1, 8/1 biotin/streptavidin ratios. The test is run using the optimal enzyme, ATP and substrate concentrations. Negative controls corresponding to each Sa-XL665 concentration must be used, as this reagent has a direct contribution to the background level.

7. INHIBITOR IC50 DETERMINATION

The kinase activity is tested over a broad range of inhibitor concentrations to generate a dose response curve. The test is generally run using the previously determined optimal assay conditions.

Terms and conditions of use
This product is the subject of one or more Patent applications licensed to Upstate, Ltd and used in a co-development agreement between Upstate Ltd. and Revvity International. The purchase of this product conveys to the purchaser the non-transferable right to use the purchased amount of the product and components of the product for research use only conducted by the purchaser. For commercial purchasers using this product for research, the purchase of this product conveys to the purchaser the non-transferable right to use the purchased amount of the product and components of the product for a six (6) month evaluation period after the date of purchase for research use only. After the six (6) month evaluation period, the purchaser must contact Chemicon International, Inc. or Upstate Ltd. or its designee to obtain a commercial research license.
The purchaser cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for any commercial purpose. The purchaser cannot use this product or its components in humans.
The purchaser may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any commercial purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for commercial purposes. Commercial purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research.
If the purchaser is not willing to accept the limitations of the limited use license, Upstate is willing to accept return of the products with a full refund. For information on commercial use of this product or obtaining a license to this product for purposes beyond non-profit research, contact the Intellectual Property department at Upstate at +001 951-676-8080 ext. 4274
This product contains material of biological origin. Use for research purposes only. Do not use in humans or for diagnostic purposes. The purchaser assumes all risk and responsibility concerning reception, handling and storage.



The information provided in this document is for reference purposes only and may not be all-inclusive. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume liability for the accuracy or completeness of the information contained herein. Users should exercise caution when handling materials as they may present unknown hazards. Revvity shall not be liable for any damages or losses resulting from handling or contact with the product, as Revvity cannot control actual methods, volumes, or conditions of use. Users are responsible for ensuring the product's suitability for their specific application. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF

Manufactured by Cisbio Bioassays - Parc Marcel Boiteux - 30200 Codolet - FRANCE

www.revvity.com

revvity

Revvity, Inc.
940 Winter Street
Waltham, MA 02451 USA
www.revvity.com

For a complete listing of our global offices, visit www.revvity.com
Copyright ©2023, Revvity, Inc. All rights reserved.